68 results
Page 2 of 4
6-K
EX-99.1
4eu8e2680
10 Nov 22
Current report (foreign)
8:30am
6-K
EX-99.1
53mlm
7 Nov 22
Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period
8:30am
6-K
EX-99.1
ngcg4r2x07go9
29 Sep 22
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
8:00am
6-K
EX-1.1
q0f o7hvby8f
16 Aug 22
Current report (foreign)
4:43pm
424B5
tfknb0v
12 Aug 22
Prospectus supplement for primary offering
1:32pm
6-K
EX-99.1
fqp2ykspu5xq1pjjz
12 Aug 22
Silence Therapeutics Announces Pricing of Underwritten Offering
6:07am
6-K
EX-99.1
mnl3u
11 Aug 22
6-K Q2 2022 Quarterly Results
5:02pm
6-K
EX-99.1
t696rxnpwkpf7x7u
16 May 22
Current report (foreign)
8:31am
6-K
EX-99.1
z54tp ivjk9nbw
25 Apr 22
Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration
8:31am
6-K
EX-99.1
m05spc l09w1kaur9
4 Apr 22
Current report (foreign)
8:31am
6-K
EX-99.1
b6qagc184
23 Mar 22
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
8:30am
6-K
EX-99.1
1ojs0cf 51rj
22 Feb 22
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
6:52am
6-K
EX-99.1
fqtlt2l
9 Feb 22
SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study
7:30am
6-K
EX-99.1
n898q0y9hzk s6hjl10v
13 Dec 21
Current report (foreign)
6:01am
6-K
EX-99.1
fkutlke 356k
16 Nov 21
Current report (foreign)
6:03am
424B5
ceagsl 00x
22 Oct 21
Prospectus supplement for primary offering
4:34pm
6-K
EX-99.1
8qsum
21 Oct 21
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
8:45am
F-3
we12rxqpxy
15 Oct 21
Shelf registration (foreign)
7:41am